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e.2012.06Abstract Background: Active management of third stage of labor is a feasible and inexpensive
intervention that helps saving thousands of women’s lives.
Objective: The aim of the study was to compare the efﬁcacy of IV ergometrine, rectal versus sub-
lingual misoprostol in active management of third stage of labor. The same protocol was applied to
Al-Jomhoria Hospital, Garunis University, Benghazi, Libya.
Methods: The study was conducted on 300 primigravida (150 Alexandria University El-Shatby
Maternity Hospital, 150 in Al-Jomhoriya Hospital, Benghazi University) who underwent normal
vaginal delivery and were divided into 3 groups according to the drug used in management of third
stage of labor (ergometrine IV, one rectal tablet of misoprostol, one sublingual tablet of misopri-
stol) All patients were closely observed for time of placental delivery, amount of blood loss by
Hb and hematocrit value pre and immediately post delivery (within 1 h), use of oxytocin and
any recorded side effects.
Results: During the follow up of Alexandria & Jamhoriya cases, it was found: 200 mcg sublingual
misopristol was more effective than 200 mcg rectal misopristol and IV ergometrine immediatelyail.com (A.E.-M.A. Fawzy),
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382 A.E.-M.A. Fawzy et al.after delivery, as it decreased the amount of blood loss [mean estimated blood loss in IV ergomet-
rine group was 331.2 ml/320.33, rectal misopristol group was 310.7/305.9, sublingual misopristol
group was 227.6/270.01, respectively. P1 = 0.001*, P2 = 0.001*/P1 = 0.036*, P2 = 0.045*]. The
most common side effects occurred in sublingual misopristol group 8% had fever, 30% had shiv-
ering in Alexandria group and 98% had shivering in Jamhoriya group.
Conclusion: Misoprostol has a revolutionary potential to reduce death and morbidity from post-
partum hemorrhage. Sublingual misopristol is a more effective uterotonic drug in management
of third stage of normal labor than IV ergometrine and rectal misoprostol.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
The third stage of labor is the time between the delivery of the
baby and delivery of the placenta. Separation of the placenta
from the uterine wall results from a combination of capillary
hemorrhage and uterine muscle contraction. The length of
the third stage of labor, and its subsequent complications, de-
pends on the length of time it takes for placental separation
and the ability of the uterine muscle to contract. It is a critical
stage in the management and prevention of post partum
hemorrhage.1,2
Postpartum hemorrhage is the most common cause of
maternal mortality and accounts for one-quarter of the mater-
nal deaths worldwide. The optimal solution for the vast major-
ity, if not all, of these tragedies is prevention, both before the
birth, by assuring that women are sufﬁciently healthy to with-
stand postpartum hemorrhage should it occur, and at the time
of the birth, by the use of physiological or active management
of labor, a management strategy that unfortunately is depen-
dent on circumstances and the availability of uterotonics.3
Active management of third stage of normal labor includes
administration of uterotonic medications after delivery of the
baby, early clamping and cutting the umbilical cord and con-
trolled traction of umbilical cord while separation and delivery
of the placenta. Uterotonic medications are oxytocin, ergot
alkaloids, syntometrine and misoprostol.4
Misoprostol is a prostaglandin E1 analog and it is one of
the cheapest prostaglandins, easily used and stored. Misopros-
tol is available in tablet form that can be administered by oral,
sublingual, rectal or vaginal route. It is stable at room temper-
ature and inexpensive. The use of misoprostol is proliferating
around the world. It is a life saving treatment for severe post-
partum hemorrhage and it is also used to reduce blood loss
during labor. It is also used in induction of labor and induction
of abortion. Also it has other nonobstetric use as it is used in
the treatment of peptic ulcer.5,6
2. Methods
The study was conducted on three hundred full term primi-
gravida (150 in Egypt & 150 in Libya) randomly allocated pre-
pared for normal vaginal delivery selected from the inpatient
clinics of El-Shatby Maternity University Hospital, University
of Alexandria and Al-Jamhoriya, University of Benghazi
(from 1 to 6/2011). They were enrolled in the study which
started after the protocol was approved by the committee of
ethics in medical research in both faculties of medicine in Alex-
andria and in Benghazi, and obtaining an informed consent
from each patient.All pregnant women were subjected to full history taking
(obstetric, medical, and surgical), complete general examina-
tion to exclude the presence of any disorders and obstetrical
examination where the high risk patients of postpartum hem-
orrhage ‘‘twins, polyhydramnios, placenta praevia, diabetes
mellitus, kidney diseases’’ were excluded.
In each center all pregnant women had underwent normal
vaginal deliveries and were divided into three groups according
to the drug used in management of the third stage of labor.
Group I: the third stage of labor was actively managed by
one ampoule of ergometrine (10 ml) IV after delivery of ante-
rior shoulder of the baby. Group II: the third stage was ac-
tively managed by one rectal tablet of misoprostol. Group
III: the third stage of labor was actively managed by one sub-
lingual tablet of misoprostol.
All patients were closely observed for time of placental
delivery, amount of blood loss by hemoglobin and hematocrit
value pre and immediately post delivery (within 1 h), {then cal-
culation of estimated blood loss using the following equation
EBL = (BV)X(HCTO-HCTf)/HCTave where:
EBL = estimated blood loss, BV: blood volume = body
weight X600 cc KG&HCTO= initial hematocrit
HCTf = ﬁnal hematocrit
HCTave = (HCTO+HCTF)/2}7
use of oxytocin and any recorded side effects.
The results of the study in Alexandria & Benghazi were tab-
ulated & analyzed with the use of appropriate statistical meth-
ods and appropriate ﬁgures and diagrams and the study was a
double-center study. The data of the study revealed the follow-
ing results.
3. Results
In Alexandria group: the mean estimated blood loss in ml in
group I (IV ergometrine) was 331.2, in group II (rectal miso-
pristol) was 310.7 and in group III (sublingual misopristol)
was 227.6 (Fig. 1). In Libyan group: the mean estimated blood
loss in ml in group I (IV ergometrine) was 220.33, in group II
(rectal misopristol) was 205.9, and in group III was 190.01. It
was found that there was statistical signiﬁcant difference be-
tween the studied groups regarding the estimated blood loss
(P< 0.05) (Table 1).
In Alexandria group: the mean of time of placental separa-
tion in minutes in group I (IV ergometrine) was 7.20, in, in
group II (rectal misopristol) was 6.72 and group III (sublingual
misopristol) was 6.21. In Libyan group: the time of placental
separation in group I (IV ergometrine) was 15.44, in group
Figure 1 Estimated blood loss in ml.
Figure 2 Time of placental separation.
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misopristol) was 13.08 (Fig. 2). It was found that there was sta-
tistical signiﬁcant difference between the studied groups
regarding the time of placental separation (P< 0.05)
(Table 2).
4. Discussion
Even with major advances in prevention of postpartum hemor-
rhage, approximately 3% of all women in a variety of popula-
tions will have severe postpartum hemorrhage with blood loss
of 1000 ml or more. Those women will require management
with correction of shock, blood and ﬂuid replacement and
homeostasis of the source of bleeding.7
Active management of labor incorporates three main inter-
ventions, administration of uterotonic medication after deliv-
ery of the baby, early clamping and cutting the umbilical
cord and controlled traction on the umbilical cord while await-
ing placental separation & delivery.8
In El-Shatby Maternity University Hospital study, it was
conducted on 150 primigravidae with low risk of developing
postpartum hemorrhage allocated for spontaneous vaginal
birth from El-Shatby Maternity University Hospital. The third
stage of labor was actively managed in all cases by early clamp-
ing and cutting the umbilical cord and controlled traction on
the umbilical cord while awaiting placental delivery then they
were divided into three groups according to the uterotonic
agent used. We compared the three groups according toTable 1 Comparison between the different studied groups regardin
Estimated blood loss (ml) Group I (IV ergometrine) Grou
Egyptian results
Range 114.92–719.29 116.7
Mean 331.1955 310.6
SD 140.26643 101.0
Libyan results
Range 50.17–853.9 25.0–
Mean 220.33 205.9
SD 190.84 180.1
P 0.001 0.001estimated blood loss, time of placental delivery, use of oxyto-
cin, presence of side effects and presence of postpartum hem-
orrhage to evaluate the efﬁcacy of IV ergometrine and rectal
misopristol versus sublingual misopristol.
In El-Shatby Maternity University Hospital we found that
200 mcg sublingual misopristol was more effective than
200 mcg rectal misopristol and IV ergometrine (10 ml) imme-
diately after delivery of the baby as it decreased the time of
placental delivery [mean time of placental separation in min-
utes in IV ergometrine group was 7.20, in rectal misopristol
group was 6.72 and sublingual misopristol group was
6.21 min, P1 = 0.045*, P2 = 0.003*] and decreased the
amount of blood loss [mean of estimated blood loss in ml
in IV ergometrine group was 331.2 in rectal misopristol
group was 310.7 and in sublingual misopristol group was
227.6. P1 = 0.001*, P2 = 0.001*]. Also we found that it is
more signiﬁcant in sublingual misopristol than the other
two groups regarding ﬁnal hematocrit level [mean ﬁnal
hematocrit in IV ergometrine group was 34.6, in rectal miso-
pristol group was 35 and in sublingual misopristol group was
35.8, P1 = 0.021*, P2 = 0.038*]. The most common side ef-
fects to occur in IV ergometrine group were: 20% had nau-
sea or vomiting, 14% had increase in blood pressure and
16% had headache. While in rectal misopristol group 10%
had fever, 32% had shivering and 2% had nausea or vomit-
ing. In sublingual misopristol group 8% had fever and 30%
had shivering. Cases which had atonic postpartum hemor-
rhage [IV ergometrine group: 6%, rectal misopristol group
2% and sublingual misopristol group no patients (0%)] were
managed by giving higher doses of misopristol, IV oxytocin
and ﬂuid transfusion, all responded to management without
need for further intervention.g estimated blood loss (Fig. 1).
p II (rectal misoprostol) Group III (sublingual misoprostol)
2–490.72 112.51–364.24
9 227.5612
73.24817
890.22 20.42–702.0
190.01
177.54
0.001
Table 2 Comparison between the different studied groups regarding time of placental separation (Fig. 2).
Time of placental separation (minute) Group I (IV ergometrine) Group II (rectal misoprostol) Group III (sublingual misoprostol)
Egyptian results
Range 2–14 5–8 4–8
Mean 7.20 6.72 6.21
SD 2.814 1.025 1.98
Libyan results
Range 5–40 5–45 10–30
Mean 15.44 13.2 13.08
SD 8.13 5.5 3.87
P 0.001 0.001 0.001
384 A.E.-M.A. Fawzy et al.In Al-Jamhoriya Hospital, Garyounis University study they
found that sublingual misopristol was more effective than IV
ergometrine in shortening the time of placental delivery but
had the same effect as rectal misopristol [mean time of placen-
tal delivery in minutes in IV ergometrine group was 15.44, in
rectal misopristol group was 13.2 and sublingual misopristol
group was 13.0 min, P1 = 0.033*, P2 = 0.433]. Also they
found that sublingual misopristol was more effective than rec-
tal misopristol and IV ergometrine in decreasing blood loss in
third stage of labor [mean of estimated blood loss in ml in IV
ergometrine group was 220.33, in rectal misopristol group was
205.9 and in sublingual misopristol group was 190.01.
P1 = 0.036*, P2 = 0.045*]. Also they found that it was more
signiﬁcant in sublingual misopristol than the other two groups
regarding ﬁnal hematocrit level [mean ﬁnal hematocrit in IV
ergometrine group was 34.27, in rectal misopristol group was
31.2 and in sublingual misopristol group was 31.77,
P1 = 0.046*, P2 = 0.0008*]. The most common side effects
to occur in IV ergometrine group were 18% had nausea and
vomiting and 8% had shivering. While in rectal misopristol
group 10% had shivering. In sublingual misopristol group
28% had shivering. Cases which had atonic postpartum hem-
orrhage [IV ergometrine group 10%, rectal misopristol group
2% and sublingual misopristol group no patients (0%)] were
managed by giving higher doses of misopristol, IV oxytocin
and ﬂuid transfusion, all responded to management without
need for further intervention.
Singh et al.9 have suggested that administration of sublin-
gual misoprostol was more effective than intravenous oxyto-
cin, and intravenous methylergometrine for active
management of the third stage of labor in a double-blind ran-
domized trial of 300 women with a healthy singleton preg-
nancy allocated into groups to receive either: 400 mcg or of
sublingual misoprostol, 5 IU of intravenous oxytocin, or
200 mcg of intravenous methylergometrine. This is matching
with our results.
Winikoff et al.10 have suggested that in settings in which use
of oxytocin is not feasible, sublingual misoprostol might be a
suitable ﬁrst-line treatment alternative for post-partum hemor-
rhage. As in this double-blind, 9348 women not exposed to
prophylactic oxytocin had blood loss measured after vaginal
delivery at four hospitals in Ecuador, Egypt, and Vietnam.
Of them: 978 (10%) women were diagnosed with primary
post-partum hemorrhage and were randomly assigned to re-
ceive 800 lg misoprostol (n= 488) or 40 IU intravenous oxy-
tocin (n= 490). Primary endpoints were cessation of active
bleeding within 20 min and additional blood loss of 300 ml
or more after treatment. Clinical equivalence of misoprostolwould be accepted if the upper bound of the 97Æ5% CI fell be-
low the predeﬁned margin of 6%. All outcomes were assessed
from the time of initial treatment. Active bleeding was con-
trolled within 20 min with study treatment alone for 440
(90%) women given misoprostol and 468 (96%) given oxytocin
(relative risk [RR] 0.94, 95% CI 0.91–0.98; crude difference
5.3%, 95% CI 2.6–8.6). Additional blood loss of 300 ml or
greater after treatment occurred for 147 (30%) women receiv-
ing misoprostol and 83 (17%) receiving oxytocin (RR 1.78,
95% CI 1.40–2.26). Shivering (229 [47%] vs 82 [17%]; RR
2.80, 95% CI 2.25–3.49) and fever (217 [44%] vs 27 [6%];
8.07, 5.52–11.8) were signiﬁcantly more common with miso-
prostol than with oxytocin. No women had hysterectomies
or died. Our results concluded better efﬁcacy of sublingual
misopristol group as it included only low risk primigravidas.
Chhabra et al.11 have suggested that a low dose of sublin-
gual misoprostol appears to be as effective as a low dose of
IV methylergometrine in the prevention of post-partum hem-
orrhage in low-risk cases. So given the advantages of its stabil-
ity at room temperature, low cost and easy route of
administration, misoprostol appears to be a better choice.
However, we found that sublingual misoprostol is more effec-
tive than IV ergometrine.11
Shivering and hyperpyrexia were the most common side ef-
fects of misoprostol. Patted et al.12 mentioned in their study
that misoprostol is associated with a signiﬁcant increase in
postpartum maternal shivering and fever. Given its proven efﬁ-
cacy for the prevention of postpartum hemorrhage, the bene-
ﬁts of misoprostol are greater than the associated risks. As
in their study 1620 women delivering at home or sub-centers
in rural India were randomized to receive misoprostol or pla-
cebo in the third stage of labor. Women were evaluated for
shivering, fever, nausea, vomiting and diarrhea at 2 and 24 h
postpartum. Symptoms were graded as absent, mild-to-moder-
ate or severe. The result of this study was women who received
misoprostol had a signiﬁcantly greater incidence of shivering
(52% vs. 17%, p< 0.001) and fever (4.2% vs. 1.1%,
p< 0.001) at 2 h postpartum compared with women who re-
ceived placebo. At 24 h, women in the misoprostol group expe-
rienced signiﬁcantly more shivering (4.6% vs. 1.4%,
p< 0.001) and fever (1.4% vs. 0.4%, p< 0.03). There were
no differences in nausea, vomiting or diarrhea between the
two groups. These results are not matching with our results
that revealed an incidence of fever in sublingual misopristol
group 8% and incidence of shivering was 30%, but this may
be explained by the difference in number of cases.
Finally, misoprostol is a drug of low-cost, easy-to-adminis-
ter, powerful uterotonic with an excellent safety proﬁle and
Active management of third stage of labor by intravenous ergometrine and rectal 385long shelf-life, misoprostol has a revolutionary potential to re-
duce death and morbidity from postpartum hemorrhage in
precisely those situations where it is most common – delivery
at home without a skilled birth attendant and sublingual route
is the most rapidly absorbable route, and a more effective uter-
otonic drug in the management of the third stage of the normal
labor, with excellent safety.
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